Piptaz (piperacillin-tazobactam) already has good anaerobic coverage. Metrogyl (metronidazole) adds overlapping anaerobic coverage, so the combination is often considered unnecessary duplication and can increase adverse effects such as nausea, diarrhea, neuropathy with prolonged metronidazole, and risk of C. difficile infection.

Use both only if the treating clinician has a specific indication, based on the infection source, cultures, local resistance pattern, or an infectious-disease/surgical protocol. Do not add Metrogyl yourself if Piptaz is already prescribed.

Also ensure:

A stewardship review identifies piperacillin-tazobactam plus metronidazole as a common potentially redundant combination, and ICU guidance advises adding metronidazole for anaerobes only when the regimen does not already include piperacillin-tazobactam. Evidence on redundant anaerobic therapy and ICU antibiotic guidance support this.